Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Colorectal Cancer

Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Albuquerque, NM
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Farmington, NM
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Farmington, NM
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Las Cruces, NM
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Las Cruces, NM
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Santa Fe, NM
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Santa Fe, NM
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Rochester, NY
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Durham, NC
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Greensboro, NC
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Greensboro, NC
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
High Point, NC
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
High Point, NC
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Washington, NC
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Washington, NC
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Winston-Salem, NC
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Columbus, OH
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Toledo, OH
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Toledo, OH
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Dunmore, PA
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Dunmore, PA
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Media, PA
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Media, PA
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Charleston, SC
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Corpus Christi, TX
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Houston, TX
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Madison, WI
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Madison, WI
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Wauwatosa, WI
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Wauwatosa, WI
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Elizabethtown, KY
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Elizabethtown, KY
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Investigational Site
mi
from
Manasquan, NJ
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Investigational Site
mi
from
Manasquan, NJ
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
mi
from
Edmonton,
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
mi
from
Edmonton,
Click here to add this to my saved trials
Evaluation of a Low-Cost High Resolution Microendoscope for the Detection of Lower Gastrointestinal Neoplasia
Evaluation of Low-Cost High Resolution Microendoscope for the Detection of Lower Gastrointestinal Neoplasia
Status: Enrolling
Updated:  1/8/2016
Mount Sinai Hospital
mi
from
New York, NY
Evaluation of a Low-Cost High Resolution Microendoscope for the Detection of Lower Gastrointestinal Neoplasia
Evaluation of Low-Cost High Resolution Microendoscope for the Detection of Lower Gastrointestinal Neoplasia
Status: Enrolling
Updated: 1/8/2016
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Effectiveness of Electronic Health Record-Based Interventions for Improving Follow-Up in Primary Care
Effectiveness of Electronic Health Record-Based Interventions for Improving Follow-Up in Primary Care
Status: Enrolling
Updated:  1/12/2016
Michael E. Debakey VA Medical Center
mi
from
Houston, TX
Effectiveness of Electronic Health Record-Based Interventions for Improving Follow-Up in Primary Care
Effectiveness of Electronic Health Record-Based Interventions for Improving Follow-Up in Primary Care
Status: Enrolling
Updated: 1/12/2016
Michael E. Debakey VA Medical Center
mi
from
Houston, TX
Click here to add this to my saved trials
Effectiveness of Electronic Health Record-Based Interventions for Improving Follow-Up in Primary Care
Effectiveness of Electronic Health Record-Based Interventions for Improving Follow-Up in Primary Care
Status: Enrolling
Updated:  1/12/2016
Scott & White Memorial Hospital
mi
from
Temple, TX
Effectiveness of Electronic Health Record-Based Interventions for Improving Follow-Up in Primary Care
Effectiveness of Electronic Health Record-Based Interventions for Improving Follow-Up in Primary Care
Status: Enrolling
Updated: 1/12/2016
Scott & White Memorial Hospital
mi
from
Temple, TX
Click here to add this to my saved trials
A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors
An Extension Study to Evaluate the Safety of Veliparib as Single Agent Therapy or in Combination With Chemotherapy in Subjects With Solid Tumors
Status: Enrolling
Updated:  1/18/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors
An Extension Study to Evaluate the Safety of Veliparib as Single Agent Therapy or in Combination With Chemotherapy in Subjects With Solid Tumors
Status: Enrolling
Updated: 1/18/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors
An Extension Study to Evaluate the Safety of Veliparib as Single Agent Therapy or in Combination With Chemotherapy in Subjects With Solid Tumors
Status: Enrolling
Updated:  1/18/2016
Clinical Research Facility
mi
from
San Antonio, TX
A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors
An Extension Study to Evaluate the Safety of Veliparib as Single Agent Therapy or in Combination With Chemotherapy in Subjects With Solid Tumors
Status: Enrolling
Updated: 1/18/2016
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors
An Extension Study to Evaluate the Safety of Veliparib as Single Agent Therapy or in Combination With Chemotherapy in Subjects With Solid Tumors
Status: Enrolling
Updated:  1/18/2016
Site Reference ID/Investigator# 117337
mi
from
Groningen,
A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors
An Extension Study to Evaluate the Safety of Veliparib as Single Agent Therapy or in Combination With Chemotherapy in Subjects With Solid Tumors
Status: Enrolling
Updated: 1/18/2016
Site Reference ID/Investigator# 117337
mi
from
Groningen,
Click here to add this to my saved trials
Capecitabine, Oxaliplatin, Selenomethionine, and Radiation Therapy in Treating Patients Undergoing Surgery For Newly Diagnosed Stage II or III Rectal Adenocarcinoma
A Phase II Study of Capecitabine, Oxaliplatin and Selenomethionine and Radiation Therapy in Patients With Stage II and III Rectal Adenocarcinoma
Status: Enrolling
Updated:  1/19/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Capecitabine, Oxaliplatin, Selenomethionine, and Radiation Therapy in Treating Patients Undergoing Surgery For Newly Diagnosed Stage II or III Rectal Adenocarcinoma
A Phase II Study of Capecitabine, Oxaliplatin and Selenomethionine and Radiation Therapy in Patients With Stage II and III Rectal Adenocarcinoma
Status: Enrolling
Updated: 1/19/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Cathartic-Free DECT Colonography for Detection of Colonic Polyps
Cathartic-Free Dual Energy Computerized Tomography (DECT) Colonography.
Status: Enrolling
Updated:  1/20/2016
Mayo Clinic
mi
from
Scottsdale, AZ
Cathartic-Free DECT Colonography for Detection of Colonic Polyps
Cathartic-Free Dual Energy Computerized Tomography (DECT) Colonography.
Status: Enrolling
Updated: 1/20/2016
Mayo Clinic
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Cathartic-Free DECT Colonography for Detection of Colonic Polyps
Cathartic-Free Dual Energy Computerized Tomography (DECT) Colonography.
Status: Enrolling
Updated:  1/20/2016
The Mayo Clinic
mi
from
Rochester, MN
Cathartic-Free DECT Colonography for Detection of Colonic Polyps
Cathartic-Free Dual Energy Computerized Tomography (DECT) Colonography.
Status: Enrolling
Updated: 1/20/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
A Phase I/II Study of RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/21/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
A Phase I/II Study of RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/21/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
A Phase I/II Study of RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/21/2016
Massachusetts General Hospital
mi
from
Boston, MA
RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
A Phase I/II Study of RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/21/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
A Phase I/II Study of RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/21/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
A Phase I/II Study of RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/21/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
Status: Enrolling
Updated:  1/22/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
Status: Enrolling
Updated: 1/22/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Cetuximab, Capecitabine and Oxaliplatin in Patients With Epidermal Growth Factor Receptor (EGFr) Expressing Metastatic Colorectal Cancer
A Phase II Study of Cetuximab Plus Biweekly Capecitabine and Oxaliplatin (C-CO2) in the Treatment of Patients With EGFR-Expressing Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/25/2016
New York University Langone Medical Center
mi
from
New York, NY
Cetuximab, Capecitabine and Oxaliplatin in Patients With Epidermal Growth Factor Receptor (EGFr) Expressing Metastatic Colorectal Cancer
A Phase II Study of Cetuximab Plus Biweekly Capecitabine and Oxaliplatin (C-CO2) in the Treatment of Patients With EGFR-Expressing Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/25/2016
New York University Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Cetuximab, Capecitabine and Oxaliplatin in Patients With Epidermal Growth Factor Receptor (EGFr) Expressing Metastatic Colorectal Cancer
A Phase II Study of Cetuximab Plus Biweekly Capecitabine and Oxaliplatin (C-CO2) in the Treatment of Patients With EGFR-Expressing Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/25/2016
Bellevue Hospital
mi
from
New York, NY
Cetuximab, Capecitabine and Oxaliplatin in Patients With Epidermal Growth Factor Receptor (EGFr) Expressing Metastatic Colorectal Cancer
A Phase II Study of Cetuximab Plus Biweekly Capecitabine and Oxaliplatin (C-CO2) in the Treatment of Patients With EGFR-Expressing Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/25/2016
Bellevue Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Reducing Sedentary Behaviors Among Colorectal Cancer Survivors
Reducing Sedentary Behaviors Among Colorectal Cancer Survivors: Cancer Survivorship Center Pilot Project
Status: Enrolling
Updated:  1/25/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Reducing Sedentary Behaviors Among Colorectal Cancer Survivors
Reducing Sedentary Behaviors Among Colorectal Cancer Survivors: Cancer Survivorship Center Pilot Project
Status: Enrolling
Updated: 1/25/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
A Randomized, Double-blind, Placebo-controlled, Phase III Study of Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo in Patients With Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum
Status: Enrolling
Updated:  1/26/2016
Comprehensive Cancer Institute
mi
from
Huntsville, AL
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
A Randomized, Double-blind, Placebo-controlled, Phase III Study of Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo in Patients With Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum
Status: Enrolling
Updated: 1/26/2016
Comprehensive Cancer Institute
mi
from
Huntsville, AL
Click here to add this to my saved trials
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
A Randomized, Double-blind, Placebo-controlled, Phase III Study of Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo in Patients With Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum
Status: Enrolling
Updated:  1/26/2016
Alaska Oncology and Hematology LLC
mi
from
Anchorage, AK
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
A Randomized, Double-blind, Placebo-controlled, Phase III Study of Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo in Patients With Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum
Status: Enrolling
Updated: 1/26/2016
Alaska Oncology and Hematology LLC
mi
from
Anchorage, AK
Click here to add this to my saved trials
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
A Randomized, Double-blind, Placebo-controlled, Phase III Study of Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo in Patients With Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum
Status: Enrolling
Updated:  1/26/2016
Arizona Clinical Research Center
mi
from
Tucson, AZ
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
A Randomized, Double-blind, Placebo-controlled, Phase III Study of Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo in Patients With Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum
Status: Enrolling
Updated: 1/26/2016
Arizona Clinical Research Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
A Randomized, Double-blind, Placebo-controlled, Phase III Study of Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo in Patients With Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum
Status: Enrolling
Updated:  1/26/2016
Northeast Arkansas Clinic
mi
from
Jonesboro, AR
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
A Randomized, Double-blind, Placebo-controlled, Phase III Study of Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo in Patients With Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum
Status: Enrolling
Updated: 1/26/2016
Northeast Arkansas Clinic
mi
from
Jonesboro, AR
Click here to add this to my saved trials
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
A Randomized, Double-blind, Placebo-controlled, Phase III Study of Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo in Patients With Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum
Status: Enrolling
Updated:  1/26/2016
Arkansas Cancer Research Center
mi
from
Little Rock, AR
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
A Randomized, Double-blind, Placebo-controlled, Phase III Study of Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo in Patients With Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum
Status: Enrolling
Updated: 1/26/2016
Arkansas Cancer Research Center
mi
from
Little Rock, AR
Click here to add this to my saved trials
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
A Randomized, Double-blind, Placebo-controlled, Phase III Study of Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo in Patients With Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum
Status: Enrolling
Updated:  1/26/2016
Little Rock Hematology & Oncology
mi
from
Little Rock, AR
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
A Randomized, Double-blind, Placebo-controlled, Phase III Study of Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo in Patients With Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum
Status: Enrolling
Updated: 1/26/2016
Little Rock Hematology & Oncology
mi
from
Little Rock, AR
Click here to add this to my saved trials
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
A Randomized, Double-blind, Placebo-controlled, Phase III Study of Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo in Patients With Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum
Status: Enrolling
Updated:  1/26/2016
Highlands Oncology Group
mi
from
Springdale, AR
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
A Randomized, Double-blind, Placebo-controlled, Phase III Study of Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo in Patients With Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum
Status: Enrolling
Updated: 1/26/2016
Highlands Oncology Group
mi
from
Springdale, AR
Click here to add this to my saved trials
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
A Randomized, Double-blind, Placebo-controlled, Phase III Study of Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo in Patients With Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum
Status: Enrolling
Updated:  1/26/2016
Comprehensive Blood and Cancer Center
mi
from
Bakersfield, CA
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
A Randomized, Double-blind, Placebo-controlled, Phase III Study of Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo in Patients With Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum
Status: Enrolling
Updated: 1/26/2016
Comprehensive Blood and Cancer Center
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
A Randomized, Double-blind, Placebo-controlled, Phase III Study of Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo in Patients With Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum
Status: Enrolling
Updated:  1/26/2016
Providence St. Joseph Medical Center
mi
from
Burbank, CA
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
A Randomized, Double-blind, Placebo-controlled, Phase III Study of Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo in Patients With Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum
Status: Enrolling
Updated: 1/26/2016
Providence St. Joseph Medical Center
mi
from
Burbank, CA
Click here to add this to my saved trials